Axa S.A. Kymera Therapeutics, Inc. Transaction History
Axa S.A.
- $32.3 Billion
- Q3 2024
A detailed history of Axa S.A. transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 109,312 shares of KYMR stock, worth $4.62 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
109,312
Previous 109,279
0.03%
Holding current value
$4.62 Million
Previous $3.26 Million
58.63%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$281 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$254 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$218 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$207 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$201 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.31B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...